Press Release: Agilent : Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics' FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis so...Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=336066